These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 4055051)

  • 1. Clinical experience with cefotaxime for the therapy of bacteremias due to gram-positive organisms.
    Schleupner CJ
    Infection; 1985; 13 Suppl 1():S28-33. PubMed ID: 4055051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of cefotaxime in serious infections.
    Karakusis PH; Feczko JM; Goodman LJ; Hanlon DM; Harris AA; Levin S; Trenholme GM
    Antimicrob Agents Chemother; 1982 Jan; 21(1):119-24. PubMed ID: 6282202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of the effect of cefotaxime in senile pneumonia caused by gram-positive and gram-negative bacteria.
    Katsunuma H
    Infection; 1985; 13 Suppl 1():S18-24. PubMed ID: 4055049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections.
    Schleupner CJ; Engle JC
    Antimicrob Agents Chemother; 1982 Feb; 21(2):327-33. PubMed ID: 6280600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of cefotaxime, a beta-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms.
    Francke EL; Neu HC
    Am J Med; 1981 Sep; 71(3):435-42. PubMed ID: 6269426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefotaxime monotherapy in septicemic patients with hematological malignancies.
    Plesner AM; Hansen MM; Nissen NI; Friis H
    Clin Ther; 1986; 9(1):97-105. PubMed ID: 3815462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of cefotaxime therapy in infections caused by gram-positive pathogens.
    Iannini PB
    Infection; 1985; 13 Suppl 1():S3-6. PubMed ID: 4055052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Staphylococcus aureus septicaemia treated with cefotaxime.
    Shah PM
    Infection; 1985; 13 Suppl 1():S34-6. PubMed ID: 4055053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefotaxime treatment of skin and skin structure infections: a multicenter study.
    LeFrock JL; McCloskey RV
    Clin Ther; 1982; 5 Suppl A():19-25. PubMed ID: 6293714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the use of cefotaxime in the treatment of skin and skin structure infections, with special reference to gram-positive pathogens.
    Karakusis PH; Trenholme GM; Levin S
    Infection; 1985; 13 Suppl 1():S46-9. PubMed ID: 4055055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of three different dosing regimens of cefotaxime for treatment of gram-negative bacteremia.
    Trenholme GM; Schmitt BA; Nelson JA; Gvazdinskas LC; Harrison BB; Parkhurst GW
    Diagn Microbiol Infect Dis; 1989; 12(1):107-11. PubMed ID: 2653713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefotaxime: efficacy and tolerance in lower respiratory tract infections caused by gram-positive cocci.
    Lode H; Glatzel PD
    Infection; 1985; 13 Suppl 1():S25-7. PubMed ID: 4055050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of cefotaxime in the treatment of gram-positive pneumonias.
    Jenkinson SG
    Infection; 1985; 13 Suppl 1():S14-7. PubMed ID: 4055045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftizoxime vs. cefotaxime--a comparative randomized multicenter study.
    Segev S; Kitzes R; Rubinstein E; Pitlik S; Samra Y; Shenkman L; Weinberg M
    Isr J Med Sci; 1988 Aug; 24(8):410-4. PubMed ID: 3045049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomised comparison of cefotaxime vs. netilmicin vs. cefotaxime plus netilmicin in the treatment of hospitalised patients with serious sepsis.
    Sage R; Nazareth B; Noone P
    Scand J Infect Dis; 1987; 19(3):331-7. PubMed ID: 3616496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of pathogenic bacteria and drug resistance in neonatal purulent meningitis].
    Zhu M; Hu Q; Mai J; Lin Z
    Zhonghua Er Ke Za Zhi; 2015 Jan; 53(1):51-6. PubMed ID: 25748405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience of cefotaxime in infections caused by gram-positive pathogens.
    Bassetti D; Solbiati M; Fraizzoli G
    Infection; 1985; 13 Suppl 1():S112-4. PubMed ID: 4055040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefotaxime for the treatment of gram-positive urinary tract infection.
    Piccinno A; Pagliarulo A
    Infection; 1985; 13 Suppl 1():S100-2. PubMed ID: 4055038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone and joint infections caused by gram-positive bacteria: treatment with cefotaxime.
    LeFrock J; Mader J; Smith B; Carr B
    Infection; 1985; 13 Suppl 1():S50-5. PubMed ID: 4055056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro interaction between ofloxacin and cefotaxime against gram-positive and gram-negative bacteria involved in serious infections.
    Gimeno C; Borja J; Navarro D; Valdés L; García-Barbal J; García-de-Lomas J
    Chemotherapy; 1998; 44(2):94-8. PubMed ID: 9551238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.